



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

December 2, 2019

Ms. Shalini Sharp  
Chief Financial Officer  
Ultragenyx Pharmaceutical Inc.  
60 Leveroni Court  
Novato, CA 94949

**Re: Ultragenyx Pharmaceutical Inc.**  
**Form 10-Q for the Quarterly Period ended June 30, 2019**  
**Exhibit No. 10.2**  
**Filed August 2, 2019**  
**File No. 001-36276**

Dear Ms. Sharp:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance